Longeveron to Present at Q1 Virtual Investor Summit Conference
Longeveron, a clinical stage biotechnology company focused on cellular therapies for chronic and aging-related conditions, announced that CEO Geoff Green will present at the Q1 Virtual Investor Summit on March 8, 2022, from 2:00 to 2:30 p.m. ET. The presentation will be available via a live webcast on the company's website, with an archived replay to follow. Longeveron's lead product, Lomecel-B, is derived from young adult bone marrow and aims to treat disorders linked to aging. The company seeks to advance its therapies toward regulatory approvals and commercialization.
- None.
- None.
MIAMI, March 02, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive Officer at Longeveron, will present at the upcoming Q1 Virtual Investor Summit on Tuesday, March 8, 2022. Details of Longeveron’s participation follow below:
- Format: Virtual Company Presentation
Date: Tuesday, March 8, 2022
Time: 2:00 - 2:30 p.m. ET
A live webcast will be available via the Investors & Media section of the Company website (www.longeveron.com). Following the presentation, an archived replay will be available on Longeveron’s website.
About the Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: info@investorsummitgroup.com
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization, and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.
Contact:
Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
Email: Brendan.payne@sternir.com
Source: Longeveron
FAQ
When is Longeveron's presentation at the Q1 Virtual Investor Summit?
Where can I watch Longeveron's presentation on March 8, 2022?
What is Longeveron's lead product?
What clinical trials is Longeveron currently sponsoring?
What is the focus of the Q1 Virtual Investor Summit?
